BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 168 produtos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Cor e Forma:Odour SolidBRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Cor e Forma:SolidPeso molecular:483.93LFM-A13
CAS:LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Fórmula:C11H8Br2N2O2Pureza:99.50%Peso molecular:360L18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Fórmula:C47H51N11O8Cor e Forma:SolidPeso molecular:897.98PROTAC BTK Degrader-10
CAS:PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].Fórmula:C42H49N11O4Cor e Forma:SolidPeso molecular:771.91BTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Fórmula:C20H25N7O2Cor e Forma:SolidPeso molecular:395.46BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Cor e Forma:Odour SolidIBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Fórmula:C22H23ClN6OCor e Forma:SolidPeso molecular:422.91Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Fórmula:C17H19N3O2Pureza:99.77%Cor e Forma:White SolidPeso molecular:297.36Ref: TM-T39130
1mg145,00€5mg250,00€10mg340,00€1mL*10mM (DMSO)356,00€25mg573,00€50mg879,00€100mg1.314,00€Zanubrutinib-D5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Fórmula:C27H29N5O3Pureza:>99.99%Cor e Forma:White SolidPeso molecular:476.58GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFórmula:C33H36N6O3SCor e Forma:SolidPeso molecular:596.74NX-5948
CAS:NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.Fórmula:C42H54N12O5Pureza:98.29%Cor e Forma:SolidPeso molecular:806.96Ref: TM-T75124
1mg80,00€5mg145,00€1mL*10mM (DMSO)178,00€10mg212,00€25mg339,00€50mg510,00€100mg708,00€N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Fórmula:C22H23ClN6OPureza:98.83%Cor e Forma:SolidPeso molecular:422.91Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Fórmula:C26H26N6O3Pureza:99.98%Cor e Forma:Yellow SolidPeso molecular:470.52Ref: TM-T4413
2mg34,00€5mg49,00€1mL*10mM (DMSO)50,00€10mg75,00€25mg146,00€50mg260,00€100mg409,00€200mg590,00€Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Cor e Forma:Odour LiquidOlmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Fórmula:C26H26N6O2SPureza:99.14% - 99.63%Cor e Forma:SolidPeso molecular:486.59Ref: TM-T6918
2mg37,00€5mg54,00€1mL*10mM (DMSO)56,00€10mg84,00€25mg130,00€50mg170,00€100mg268,00€200mg437,00€Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Fórmula:C29H29ClN6O4Pureza:99.22%Cor e Forma:SolidPeso molecular:561.03Ref: TM-T9072
2mg38,00€5mg57,00€1mL*10mM (DMSO)71,00€10mg90,00€25mg178,00€50mg334,00€100mg497,00€200mg712,00€BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Fórmula:C32H30F2N4O4Pureza:99.44% - 99.76%Cor e Forma:SolidPeso molecular:572.6Ref: TM-T5138
1mg105,00€2mg165,00€5mg289,00€1mL*10mM (DMSO)358,00€10mg447,00€25mg715,00€50mg964,00€100mg1.243,00€200mg1.693,00€CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Fórmula:C34H37N5O4Pureza:97.69% - 97.88%Cor e Forma:White SolidPeso molecular:579.69(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Fórmula:C11H8Br2N2O2Pureza:99.88%Cor e Forma:SolidPeso molecular:360
